Mark J Enyedy
CIK 1586965 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3535 GENERAL ATOMICS COURT, SUITE 200
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMRN | Director | 21,040 | $57.32 | $1.21M | $0 | 4 | 2026-06-04 |
| CRL | Director | 2,384 | $358.53 | $854.7K | $0 | 2 | 2026-05-11 |
| ImmunoGen, Inc. (IMGN) Delisted | CHIEF EXECUTIVE OFFICER | 0 | $31.23 | $0 | -$52.99M | 22 | 2024-02-12 |
| LogicBio Therapeutics, Inc. (LOGC) Delisted | Director | 0 | $7.06 | $0 | $0 | 6 | 2022-11-17 |
| AKBA | Director | 31,143 | $0.55 | $17.0K | $0 | 3 | 2020-06-09 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-13 |
| FATE | Director | — | $1.98 | — | $0 | 3 | 2017-05-04 |
Recent Filings · Page 3 of 5
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-08 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-02 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | +3,849 | $21.2K | EDGAR |
| 2021-06-14 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-09 | ImmunoGen, Inc. (IMGN) Delisted | Mixed | −10,000 | $0 | EDGAR |
| 2021-01-04 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Exer (M) | +2,921 | $0 | EDGAR |
| 2020-07-02 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | +5,241 | $20.5K | EDGAR |
| 2020-06-23 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-09 | AKBA | Grant (A) | +13,700 | $0 | EDGAR |
| 2020-03-19 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-25 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −55,222 | -$275.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.